Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.

  title={Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.},
  author={J. Szulc-Kuberska and Henryk Stępień and Andrzej Klimek and Dorota Cieślak},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  pages={643 - 645}
Secretion of prolactin in nine patients with amyotrophic lateral sclerosis and in seven healthy men was investigated with the use of metoclopramide stimulation and bromocriptine inhibition tests. Blood serum prolactin concentration was determined in the basal state and 30, 60 and 120 minutes after oral administration of 10 mg metoclopramide or 2.5 mg bromocriptine. A period of 3 days intervened between testing each drug in the same individual. It was shown that basal prolactin levels in… Expand
Decreased dopaminergic control of prolactin secretion in male obesity: normalization by fasting.
Although decreased PRL synthesis, reduced cell membrane permeability, and inadequate MET stimulation are plausible mechanisms by which the reduced PRL responsiveness to MET could be explained in the obese patients, neither is likely in view of the fact that the lactotrophs responded promptly to thyrotropin-releasing hormone (TRH) in the fed obese patients. Expand
Neuropharmacology of amyotrophic lateral sclerosis.
This chapter describes the neuropharmacology of amyotrophic lateral sclerosis as expressed on transmitter-related enzymes and receptors in the central nervous system and skeletal muscle, with emphasis on cholinergic mechanisms. Expand
A Review of Hormonal Findings in Cluster Headache. Evidence for Hypothalamic Involvement
The hormonal abnormalities in cluster headache support disorders of hypothalamic function, which are known to cause cluster headache and to support the role of the hypothalamus in this illness. Expand
Amyotrophic lateral sclerosis and prolactinoma.
Investigations revealed the co-existence of a pituitary adenoma of the prolactinoma type and the possible relation between endocrinological disturbances and this neurological disease is discussed. Expand
Neuroendocrinology of Neurodegenerative Diseases
In the present review, some of the endocrine changes characterising three major neurodegenerative diseases are summarized and the contribution of disease transgenic models to elucidate such alterations are focused on. Expand
Insights from Transgenic Mouse Models
The nervous system plays a key role in the regulation of neuroendocrine axes and, in turn, the released neurohormones modulate the activity of different brain regions. Neurodegenerative diseases,Expand
Motor neuron disorders with other diseases and exposures
This chapter reviews the evidence relating to the occurrence of ALS/MND in relation to physical exposures and endocrine disease and provides specific neurophysiological features. Expand


Comparison of metoclopramide with other dynamic tests of prolactin secretion.
A 10 mg dose produces a larger, more sustained increment in serum PRL than other agents used to evaluate prolactin reserve, and metoclopramide may be useful for dynamic testing of PRL release. Expand
The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome.
  • W. Jeske
  • Medicine
  • Acta endocrinologica
  • 1979
It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while theresponse to L-DOPA was usually retained. Expand
Very high intravenous doses of thyrotropin-releasing hormone (TRH) given to 12 patients with amyotrophic lateral sclerosis produced a moderate to marked improvement of functions caused by deficiency of lower motor neurons (weakness) and upperMotor neurons (spasticity). Expand
Metoclopramide stimulates prolactin secretion in man.
Serum prolactin concentrations increased approximately 6-fold after oral or intravenous administration of 10 mg of metoclopramide to adult men, which is consistent with the possibility that metoclobramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactIn inhibitory factor. Expand
Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa.
Defects in central dopamine metabolism, inferred from these tests applicable to the living patient, evidently may attend neurologic disorders which are unresponsive to precursor loading with levodopa. Expand
Neural control of prolactin secretion in man
INTRODUCTION THE INTRODUCTION of reliable radioimmunoassay methods for measurement of prolactin (PRL) in human blood has made it possible to study the factors that regulate the secretion of thisExpand
Letter: Metaclopramide and prolactin.
Phenobarbitone and metoclopramide show similar effects on xylose absorption both in vivo and in vitro but there is no such correlation with propantheline. Expand
Reduced lumbar cerebrospinal fluid corticotropin releasing factor (CRF) levels in amyotrophic lateral sclerosis
Results suggests that CRF may be related in the pathophysiology of ALS, and this value was significantly lower in the patients with ALS than in controls. Expand
Dopamine/neuroleptic receptors in basal hypothalamus and pituitary.
The hypothesis that dopamine may act directly as a prolactin release inhibiting factor (PIF) rather than releasing PIF from adjacent nerve terminals in the median eminence is supported. Expand
Amyotrophic lateral sclerosis: Alterations in neurotransmitter receptors
Reductions in glycine and muscarinic receptors were highly correlated with the degree of motor neuron loss found in the amyotrophic lateral sclerosis patients, pointing out the usefulness of this receptor mapping technique in understanding the changes in neuronal populations that occur in the degenerative neurological diseases. Expand